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Background: Opioid agonist treatment (OAT) is an important pillar in the treatment of
individuals using opioids and its continuation during imprisonment is recommended.
Despite this knowledge access to and continuation of OAT is still limited in many countries.
The forced discontinuation during pre-trial detention can cause severe withdrawal
symptoms, which in turn may significantly impair the defendant's ability to exercise
granted procedural participation rights. Furthermore, it can be argued that forced
discontinuation of a desired treatment represents a form of a compulsory intervention.
Aims: The present study was developed against the backdrop of a recent ruling by the
European Court of Human Rights (Wenner vs. Germany). It intended to examine how defense
lawyers dealing with detained persons using opioids view and assess the accessibility of OAT
in pre-trial detention as well as during imprisonment in different parts of Switzerland.
Methods: Using a qualitative approach, we interviewed 11 defense lawyers from three
different cantons of Switzerland with multiple years of experience in providing legal
representation to more than 220 defendants using heroin. The interviews were
analyzed with QSR NVIVO 11 for Windows. A qualitative content analysis approach
was used to evaluate findings.
Results: Defenders who had been exposed to the opioid crisis during the course of their
legal career had adopted a positive attitude towards OAT and associated it with a
stabilizing influence on their clients, an improvement in criminal prognosis, and a reduction
in recidivism. They were generally of the opinion that access to OAT had improved,
however identified a considerable variance in different penitentiaries, which were mediatedg May 2020 | Volume 11 | Article 3951
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Frontiers in Psychiatry | www.frontiersin.orby attitudes of staff and authorities. Based on the assessments of the defense lawyers, it
can be estimated that the initiation of OAT especially during pre-trial detention is
challenging. The predominant aim of OAT in a variety of Swiss prisons still seems to
focus on a discontinuation, mediated by a forced reduction of medication. Some of the
interventions reported are not in line with the principle of equivalence and strongly contrast
the recommendations of the Council of Europe.Keywords: opioid agonist maintenance treatment, prison, qualitative research, defense attorneys, forced withdrawalINTRODUCTION
Modern opioid agonist treatment (OAT) with methadone,
buprenorphine or other prescribed opioids such as morphine is
an important strategy in the treatment of patients with an opioid
use disorder (1–4). This form of therapy is associated with an
improvement in the individual's health and also leads, among
other things, to a reduction in the incidence of HIV and drug-
related crime (5–9). Because of these positive effects, methadone
and buprenorphine were included in the World Health
Organization (WHO) model list of essential medicines almost
15 years ago and have remained on it ever since (10, 11). OAT is
also an important pillar in the treatment of opioid addiction in
jails and prisons, and various professional medical associations
recommend the continuation of therapy during imprisonment
(12–14). In this context, it should be emphasized that the
overdose-related mortality rate of people with heroin addiction
is particularly high after withdrawal under detention conditions
and following release without established aftercare (15–17).
Despite this knowledge, access to OAT is still limited in many
countries, especially for detained persons (18, 19). For example,
in September 2016, the European Court of Human Rights
(ECtHR) found Germany in breach of Article 3 of the
European Convention of Human Rights in denying an inmate
access to OAT, even though the applicant had expressed a clear
wish to continue with the therapy he had started before he was
sentenced to prison. More specifically, the court criticized that
authorities had made that decision without having consulted an
independent medical expert and without being able to prove the
superiority of another form of treatment. This discontinuation of
OAT thus amounted to inhuman treatment according to the
ruling of the ECtHR (European Court of Human Rights, Wenner
v. Germany—62303/13; Judgment of 1 September 2016).
From a medico-legal perspective, the forced discontinuation
of OAT during pre-trial detention can cause severe withdrawal
symptoms, which in turnmay significantly impair the defendant's
ability to exercise granted procedural participation rights.
In medico-ethical terms, it can be argued that forced
terminations and/or terminations effected against the patient's
will of a desired methadone maintenance treatment represent a
form of a compulsory intervention (20–22).
Switzerland in particular adopted early on a harm-reduction
approach that included low-threshold OAT accessibility, an
approach that is currently considered “an ethically legitimate
social strategy” (23). Today there are an estimated 30,000
persons or less using heroin in Switzerland, of whom theg 2majority have had OAT on any given day (24). Furthermore,
there is even one prison offering not just OAT but also heroin-
assisted treatment, which is available to patients who do not
respond adequately to methadone and/or buprenorphine and
who have been highly dependent for several years (25).
Despite this progress, it is also known, however, that the
group of patients with opioid dependence are among those who
are particularly stigmatized in a prison setting, and that
treatment of substance use is perceived as particularly
complicated by prison supervisory staff (26, 27). There is also
anecdotal evidence that individual positive or negative attitudes
towards the effectiveness of OAT among Swiss prison staff
influence its “real life” availability to detained persons, even if
access is regulated by high-level prison authorities.
The present study, which was developed in collaboration with
the Law Institute of the University of Berne against the backdrop
of the ECtHR's ruling, was intended to examine the questions of
how defense lawyers representing detained persons using
opioids, perceive and experience the work with their clients
and how they view and assess the accessibility of OAT in pre-
trial detention as well as during imprisonment. This approach
was chosen over a written survey of prison authorities in order to
reduce the likelihood of socially desirable responses. The aim was
therefore not to get a quantitative impression of the quantities
and frequencies of a phenomenon such as withholding OAT, or
to pillory single detention facilities, but to depict the personal
experiences of defense lawyers in dealing with a clientele using
opioids. It is precisely the depiction of personal experiences and
attitudes that make it easier to understand whether or not there
are problems in this context when regarded from a legal
perspective, what kind of difficulties these are, and whether
they have any wishes for physicians (or any other group of
people) (28). The knowledge of the position of the ECtHR and
the attitudes of Swiss lawyers can, in the view of the authors, be
used for purposes of comparison in other member states of the
Council of Europe and thus open up interesting perspectives for
an international readership.METHODS
Study Design and Reporting
This study was designed with an exploratory qualitative approach
and is reported according to the consolidated criteria for reporting
qualitative research (COREQ) guidelines (29).May 2020 | Volume 11 | Article 395
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A mixed purposive and snowball sampling procedure was used
for participant selection. We focused specifically on individuals
who appeared to be able to provide rich data of the phenomenon
of interest, that is, having current personal experience with
individuals using substances in criminal justice proceedings.
To achieve greater variation of themes and motives, we
recruited subjects from three different German-speaking
cantons of Switzerland. Furthermore, the sample incorporated
diversity with regards to: (a) work experience, (b) legal focus, (c)
teaching experience (d), gender and (e) age. The exclusion
criterion was unwillingness to give written informed consent.
The research team pursued two strategies to contact potential
participants: a.) an opt-in letter (374 words) was sent to certified
defense lawyers in the cantons of Berne and Zurich, inviting
them to participate. Following a time period of 7–8 days all
candidates were then approached by a team member via
telephone, providing them with more details regarding the
research and answering their questions, and b.) individuals
who appeared to be especially information-rich were
additionally contacted by e-mail or phone and asked to
participate; these individuals were previously identified by legal
scholars and a high court judge from the cantons of Lucerne and
Berne. The latter approach was undertaken to broaden the
spectrum and to reach saturation. Saturation is commonly
defined as the point when no new themes arise. The subjects
provided additional basic biographical data.Data Collection and Interview
To ascertain participants' perceptions and experiences in relation
to: (1) the legal representation of a clientele using substances, (2)
the peculiarities of OAT delivered in pre-trial detention and
during the serving of sentences and therapeutic measures, and
(3) the further course of their clients' lives after release from
prison, we conducted single, semi-structured, in-depth
interviews lasting between 60 and 90 min. We used a self-
developed and flexible interview guide, which can be found in
the appendix. Two female researchers (EA and AB) conducted
the interviews. EA was at the time a Master's student at the
faculty of law preparing a thesis under the supervision of ML, a
forensic psychiatrist and faculty member of the medical school.
AB, who was an attending physician at the Psychiatric University
Hospital, Zurich with experience in the provision of OAT as well
as in conducting qualitative interviews, trained EA and
supervised the initial interviews. The research team itself had
gathered previous experience employing qualitative research
methodology at the intersection of law and medicine. Results
have been reported elsewhere (30, 31).
Before the interviews, participants had an understanding that
EA had a legal background and that the research represented a
collaboration between the Institute for Penal Law and
Criminology, the Institute for Forensic Medicine and psychiatric
institutions and that the research would address defense lawyers'
experiences with clients suffering from opioid dependence.
All interviews were conducted in Swiss or Standard German.
Open-ended questions and non-leading probes were used toFrontiers in Psychiatry | www.frontiersin.org 3encourage participants to speak freely and to elaborate on their
statements. Paraphrasing and summarizing main points during
the interviews helped minimize misunderstandings and clarify
ambiguous statements. Interviews were—with the exception of
the initial interview—conducted on a one-to-one basis and were
digitally recorded. Field notes were taken after the interview
By grounding the questions in participants' practice
experiences, and by reformulating the questions, we sought to
avoid generalized responses. The location of the interview was
chosen by the participants. This was done to create an
atmosphere which allowed for eliciting more “private”
opinions and experiences. All interviews were carried out at
the participants' workplace. There were no repeat interviews.
Data Analysis
Interviews were digitally recorded using Olympus DS-7000 and
then transcribed verbatim into Standard German. Whereas Swiss
German is commonly only spoken, Standard German is
traditionally used in writing and transcription in Switzerland,
which is why all interviews were written down in Standard
German using a word processor (Microsoft Word). After
removing identifying information, each transcript was assigned
a code number. The transcripts were not returned to
the participants.
Qualitative analysis of the interview data was done
independently, initially by AE, and subsequently for the
purpose of this publication by AB and ML. AB and ML
analyzed the material blinded as to participant identity, then
reviewed the initial categories and themes identified by AE. A
comparison thematic approach, identifying common and new
themes related to the research aims was used. For this research,
the interviews were analyzed with QSR NVIVO 11 for Windows,
a qualitative data analysis software (QDAS) (32). This software
was used to organize the semi-structured interviews, to set up
case nodes, to code emerging themes and to visualize the data.
Coding centered on identifying common and unique themes
related to the research aims, as well as omissions within the
interview transcripts.
The coding process ensured a systematic, comprehensive and
detailed reading of each interview transcript. First, the coders
familiarized themselves with the transcripts in order to identify
the different subjects of interest. After several interviews had
been coded, the categories for the study were redefined, reviewed
and revised in a consensual manner at meetings between AB and
ML. When there was disagreement regarding the coded material,
ML applied the final code. As a result of the coding process and
for the purpose of this paper, four main categories were identified
and selected: a) personal stance on OAT, b) access to OAT, c)
course of OAT, and d) difficulties and room for improvement.
An overview of the categories is shown in Figure 1.
To illustrate the categories and for reporting purposes, examples
of coded quotations were chosen by AE and ML and translated
from German into English by ML. Google Translate as well as
Deepl were used to support and simplify this translation process.
Quotations were then improved by a bilingual German/English
speaker (ML) and edited by an English native speaker (Heather
Murray) to ensure readability for an international audience.May 2020 | Volume 11 | Article 395
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SPSS version 24.RESULTS
Sample Descriptions
During this study the research team established contact (face to
face, telephone or e-mail correspondence) with 58 potential
participants. Of those, 47 declined to participate. Barriers to
participation included for most lack of experience with
defendants using substances, followed by lack of time and lack
of interest in the research topic. One of the defense attorneys
explained his non-participation in writing (lack of experience),
but emphasized the importance of such research projects.
In total, 11 subjects provided their written, informed consent.
All completed the interview. None of the participants withdrew
their consent at a later time. A detailed flowchart of theFrontiers in Psychiatry | www.frontiersin.org 4recruitment process can be found in Figure 2. The sample (n =
11) was composed of a higher percentage of male defense
attorneys (81%) than of females (18.2%). The mean age of the
participants was 45 years (± 9 years) with an average of 16 years
(± 9 years) years passing since taking the bar examination. All had
experience in criminal law; additionally, 54.5% had experience in
civil law and 9.1% in commercial criminal law (Table 1).
Over the course of their career, about half of the defense
attorneys interviewed had personally represented more than 20
clients using opioids. Just over a quarter had represented 30 or
more such individuals, while a fifth had represented fewer than
five clients with such a disorder (Figure 3).
Personal Stance Towards Opioid Agonist
Therapy During Times of Detention
One of the first themes to arise was the value that participants
accorded to OAT for their legal practice, specifically when
dealing with clients using opioids during the early stages ofFIGURE 1 | Main categories of lawyers' experience with OAT.FIGURE 2 | Flow diagram of the study recruitment procedure.May 2020 | Volume 11 | Article 395
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state prosecutor (Figure 4).
The defense lawyers interviewed in the context of this study
had developed—almost without exception—a positive attitude
towards OAT over the course of their legal careers. They
perceived it as a “necessary” and “good thing”. Many
substantiated this with their own case experience, in which
they had come to the conclusion that it was OAT that made
defense possible for clients with heroin addiction in the
first place.Fronti“I think it is a very important instrument—a very
important instrument especially for the peopleers in Psychiatry | www.frontiersin.org 5concerned. But of course also for us as defense
lawyers, for us as law enforcement authorities, if you
want to include the public prosecutor's office or the
court, because, um, you can work with them, let's say in
a decent, um, relationship—in a more humane
relationship with them. Because in the end you have
to talk to them, you have to question them, yes, you
have to work together and that of course makes it easier
if someone does not—I say it in the vernacular—need to
go “cold turkey”.
And just, yes, somehow the person must be able to live
(through that) and must not be oppressed or put under
so much stress, because this is bordering on torture,
basically, if someone is taken directly in from the streets
and then simply put on a cold withdrawal.”
Attorney 10Multiple times the lawyers also cited a favorable influence on
the legal prognosis and recidivism as well as a reduction in
procurement crime as reasons for their positive attitudes. A few
skeptical comments questioned whether OAT was really a
sustainable or long-term solution for those affected.“It is something very important, very central, um,
especially in the area of rehabilitation, improvement
of legal prognosis, very important, a very central topic.
Almost more important than the penal system itself.”
Attorney 04There were also highly distinct positions with regard to its
classification as a “government drug” in the sense that the state
steps in and acts as a “drug-dealer”. Although some expressed the
view that this label was “formally” correct, it was the
predominant opinion that it is a “superficial contemplation”, a
“political statement that has little to do with practice” and
“populist nonsense” . Instead, OAT was considered a
“pragmatic, economic approach” that helped to steer
“addiction in an orderly fashion” and that one had a “social
responsibility” towards those affected.“Yes, that may be true at first sight, but the question is
different, I mean what—what costs the state more, if
you don't offer substitution afterwards—and the people
just fall back into the procurement crime and then you
re-examine it…—uh, again conduct criminal
proceedings etc. and so on. Then in the end it costs
the state a lot more than if it offers substitution and the
chance to get these people off the streets, away from
drugs. I think the state gets a lot more out of it, so—it
may be true, but it is certainly well invested money and
the bottom line is that the state certainly saves a lot of
money if it offers this possibility.”
Attorney 06
“Substitution—is a controlled release of substance for
someone who has an addictive disorder; for me this is
nothing other than a treatment (…) analogous to if
someone, um, has cancer or, um, I don't know, aTABLE 1 | Baseline demographics of participants.
Sociodemographic
variables
N (%) Mean
(SD)
Age, Years 45 (9)
Sex
Male 9 (81.8)
Female 2 (18.2)
Field of legal expertise
Criminal law, yes 11 (100)
Civil law, yes 6 (54.5)
Commercial criminal law,
yes
1 (9.1)
Certified specialist
attorney at criminal law
(SAV)
Yes 4 (36.4)
No 7 (63.6)
Time since accreditation
as certified specialist at
criminal law (SAV) year
2015 3 (27.3)
2016 1 (9.1)
2017/2018 1 (9.1)
Unknown 6 (54.5)
Time since bar
examination, years
16 (9)
Teaching experience
Yes 3 (27.3)
No 8 (72.7)
International work
experience
Yes 2 (18.2)
No 9 (81.8)
Work experience canton
Bern
Yes 11
(100.0)
No 0 (0.0)
Work experience in
cantons other than Bern
0 2 (18.2)
1–5 5 (45.5)
>5 4 (36.4)
Current personal
experience with individuals
using substances
Yes 11
(100.0)
No 0 (0.0)May 2020 | Volume 11 | Article 395
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Frontimigraine—a strong migraine, or–or–or, um, strong
pain after surgery, then they also, um, get, um—then
they also get strong painkillers, which can also be
opiates in some circumstances … and nobody would
think that they are on drugs at the expense of the state.
So I think that's populist nonsense.”
Attorney 07Access to OAT During Times of Detention
Participants stressed that there is a considerable variation in the
accessibility of OAT in the different penitentiaries (Figure 5).
The interviewees described institutions in which access to OAT
was made either easy or challenging at all stages of criminal
procedures, i.e. during police custody or in pre-trial detention,
when serving custodial sentences in secure prisons or in the
context of therapeutic measures.
Factors that influence accessibility are—in the eyes of the
interviewees—the directorate of the detention institution, the
health service staff, the medical doctor on call, and the public
prosecutor's office.“Region B. very difficult. So it also depends insanely on
how it is run, how the prison director looks at it, how
the health service is organized, how easily the prison
doctor is reachable, whether he is interested or not, so it
also depends on the people.”
Attorney 10
“I've just had a case, maybe half a year ago, there is one,
um, a long-time drug addict, who is an addict—he'sers in Psychiatry | www.frontiersin.org 7perhaps fifty today—for 30 years, has also always
refused therapy, and he was, um, recently arrested
again, and there it was like that, that he demanded
the substitute for himself after the arrest, because he did
not want a cold withdrawal, and that was denied him
in a first phase, however. Um, so the doctors started to
give it to him first, and then the public prosecutor
intervened—the public prosecutor's office—and then
they, um, ver…—didn't give it to him anymore, and
then he—he went in—on hunger strike, so he simply
didn't accept any more food until they gave it back to
him. After three or four days they gave it back to him,
maybe faster—I don't know how long it went on, in any
case he went on strike and he got the substitute back.”
Attorney 05Their own influence on prescription practices in individual
cases was perceived as extremely low.“But intervening there as a defender—that is … phew
… I mean, in the end they have to—I mean that's,
prison is prison, that's the way it is, but they can - they
can report their concerns or their wishes or their
suggestions to the staff and—and that's it. In the end
it's a medical problem and it's not up to the lawyer to
say, um, it's still, why are you decreasing the
medication? (…) At most, I told clients you have to
talk to the doctor, you have to tell him that you need
more and that's not possible.”
Attorney 01FIGURE 5 | Access to opioid agonist therapy during times of detention.May 2020 | Volume 11 | Article 395
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OAT offered to detained persons was insufficient for example
in respect to dosage, particularly under pre-trial detention
conditions - a situation that was experienced as particularly
difficult. Some defense attorneys had observed that access to
medication was restricted specifically to obtain a confession.Fronti“Especially the police. Just that they delayed [access] to
it, that they also say, yes, I know, you are now in “cold
turkey”, but now we do this questioning first and then
we see if we can organize something, but now we have
to talk to you first. And for me this really borders on
torture. They don't say: you, if you don't make a
statement, then you just don't get anything. They
don't say it like that, of course, but they say, look,
now we have to do all this first and then we can see if
you can get something afterwards, but first we have to
make a few phone calls (…) A little in that style, and I
have to ask myself what is more urgent now, the health
needs of this person, or getting some statements, which
will be put in some files and maybe a week later be read
by the prosecutor. (…)”
Attorney 10However, the situation is perceived as being less acute since
the opioid crisis has subsided. The defense attorneys
distinguished relat ively dichotomously between the
continuation of an OAT started outside the prison and the
initiation of a new treatment. While the former is possible in
most prisons, the latter has become almost impossible.“If they didn't have that before, they had big problems.
And uhm, I don't remember when - methadone and
heroin maintenance were introduced in prison or in
detention. I can't remember when, but since then there
were no problems for those who had already been
attached to a program before, i.e. outside, they
usually had no problems with the continuation of the
substitution treatment in detention.”
Attorney 08In this context, comparisons were also made with
prescriptions for other drugs. In particular, the continuation of
methylphenidate is perceived as even more difficult as
obtaining OAT.“At least I never got a letter from prison, I'm not getting
my methadone or … that was somehow never an issue.
Then the public health officers were involved and that
was always actually—actually no problem. Quite
different with other drugs, right so if someone said I
need e.g., um, Ritalin! Oh well, because of ADHD—
then it was always a “shit pile”. (The prison doctor
said): Ritalin, uh-uh no and all that! No, you don't need
that and so on. Do you have a prescription from the
doctor who's treating you and so on? And then the
client had to call his family and when he finally had it,ers in Psychiatry | www.frontiersin.org 8then the doctor said, no, the last prescription was three
years ago. Ritalin is never—it is much more difficult
than methadone.”
Attorney 06In addition, respondents divulged that clients were not
treated with OAT after arrest, despite a reported heroin
addiction. Instead, withdrawal symptoms were treated with
other substances such as benzodiazepines. Clients had
complained to their lawyers about this on several occasions.“It is not a substitution in itself, but it looks rather as if
sedatives, sleeping pills are administered, not necessarily
methadone. Now also in a concrete case, I have a client in,
um, pre-trial detention. She does not get methadone, but
Valium®, Stilnox®, sleeping pills. She does get drugs, but
she does not get a substitution treatment.
But I know from other clients that I've had before that
this is not really a substitution treatment, but more a
symptom treatment. Pain—they try to, uh, to suppress
pain, and they give sleeping pills, so that they can sleep.
Obviously not enough from the client's point of view.”
Attorney 07Course of OAT During Times of Detention
From the point of view of the lawyers interviewed, most institutions
aim to discontinue OAT and to induce long-term abstinence,
especially after completion of the main trial (Figure 6).
The majority of respondents was in accordance with this
therapeutic aim and advised their clients in this direction. This
was particularly true when the clients were sentenced to a
therapeutic measure according to the Swiss Criminal Code.“That is actually always the aim, unless it is a very long-
lasting substance abuse with a long history and one
says, yes, it is rather the aim to substitute. But in most
cases it is first and foremost the aim to achieve
complete abstinence.”
Attorney 04
“Actually, I think it's right that you don't just provide a
substitute for anyone who—anyone who wants to or is
involved in a drug-related criminal case as the accused.
I think maybe you should try to find your way back to
abstinence with those people—if the addictive behavior
is not so deeply ground in—to treat and support them.”
Attorney 08In order to achieve this aim, OAT is usually tapered out
during the prison stay. According to the interviewees' experience,
reduction steps are initiated and driven by prison staff or
legal authorities.“But of course the authorities or the doctors are pushing
a little here and there and they say, so, now let's try
again, we'll take a little more away … reduce … I have
the feeling that the doctors and authorities are aimingMay 2020 | Volume 11 | Article 395
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Frontifor those dose reductions (…) And I don't think it's a
«request show», either.”
Attorney 01In addition to a dose reduction driven for therapeutic
motives, the interviews also showed that dose reduction is used
as a disciplinary measure.“For example, as punishment and that's of course a
huge problem for these people, um, if they get that as
punishment, because then—then they riot even more,
they can't understand it at all, they're not rational, or,
they don't see a causal relationship.”
Attorney 03Another major factor in dose reduction is the family's desire
to encourage detained family members to discontinue opioid
maintenance treatment.“And, so then there are often the parents behind it and
they say: Now look, now you are in prison, now you can
get away from this [methadone]stuff, so that you're
done with it once you get released.”
Attorney 01Ultimately, the detained persons themselves push ahead with
the discontinuation of OAT, when they perceive this as an
opportunity to live a life free of any substances.“And the clients say: No, this is the moment now. I have
been taken in by the police. This is my chance to stop
using and I want to do it cold turkey. Bam. And then I
go in and I talk to them and ask what they need and
then there's usually a little bit of back and forth. And
they ask me for as many cigarette packets as I can bring,
or for a couple of kilos of chocolate and then they
basically self-medicate, so to speak.”
Attorney 10ers in Psychiatry | www.frontiersin.org 9On the other hand, an increase in the dosage is always driven
by the detained persons. However, considerable resistance by
staff is described in this context. In no case did the defenders
report that the dose had been increased because, for example,
there had been co-consumption.Well, in one case I can remember how they had to go
back up after a reduction of methadone, because
somehow it just didn't work out at all for the client.
But as a rule of thumb, I think that they want to come
down with these substances.
Attorney 01Room for Improvement
Despite shortcomings, the defense lawyers interviewed were
generally of the opinion that there was relatively little need for
action with regard to OAT in Switzerland (Figure 7). The
majority of those interviewed had come to this conclusion
because they had received few(er) complaints from their clients
and had generally noticed a decline in clients with opioid misuse
and/or drug-related crime. In this context, a comparison was also
made with neighboring countries and the USA. Some of the
Swiss defense lawyers were well informed about the course of the
opioid crisis there.“But otherwise I actually have the impression that the
level, as it is now in Switzerland, is quite exemplary in
comparison with other countries, yes.”
Attorney 09Against the background of the problems reported with access
to OAT under pre-trial conditions, it was not surprising that
most defense lawyers mentioned the need for improvement in
this area. In this context, it was emphasized that an OAT should
be started as quickly and with as low a threshold as possible.
Occasionally, the discontinuation and tapering out of OATFIGURE 6 | Course of opioid agonist therapy during times of detention.May 2020 | Volume 11 | Article 395
Buadze et al. Opioid Agonist Treatment in Prisonduring transition from pre-trial to prison was criticized, but this
was then relativized again by the stricter regime prevailing in a
closed prison setting.Fronti“Something that could be improved is that if clients are
arrested who are acutely addicted to drugs and want
methadone substitution, that this could be introduced
more quickly.”
Attorney 11Another aspect that was highlighted was the need to raise
awareness among law enforcement officers for the needs of
individuals using heroin. According to the respondents, a
strong focus should be placed on the younger generation of
police officers who did not experience the opioid crisis in
Switzerland in the early 1990s. Here a clear determination of
the criminal defense lawyers became noticeable to preserve what
had been achieved since then.“But I believe that this is an issue on which we must
continue to be sensitive. We also need to sensitize new
police officers, people in law enforcement, in particular,
and say, be careful, you have to deal with [opioid-using
individuals] differently. You have to be careful at the
very beginning. There must be procedures in place that
run virtually automatically. Even in the first few hours
you need someone to ask about people's needs. And this
person needs to find out whether the defendant is
enrolled in an existing program or whether a new one
has to be started.”
Attorney 10A need for improvement was also advocated in the area of
psycho-education and aftercare after release from prison.ers in Psychiatry | www.frontiersin.org 10“If you can arrange for that during the time served, so
that they can enter a program immediately after
release, then that would be quite meaningful.”
Attorney 01Those defense lawyers who had clients who had died of an
overdose following prison release had begun informing their
clients themselves about the loss of tolerance after withdrawal.And that's something I always tell clients when they
were abruptly withdrawn in pre-trial detention. You
really try to sensitize them for the fact that this is really
dangerous when they get out and—and just start again.
Attorney 05At the level of society as a whole, it was also desirable that
information about the risks of drugs should be provided earlier
and more intensively during adolescence. There were also
isolated calls for research into better substitution agents, the
side effect profile of which should be more favorable. The
expectations and wishes towards the development of new
drugs for the pharmaceutical treatment of opioid using
individuals went beyond what is understood as opioid agonist
treatment from a medical perspective.“Yes, there is a need for action in the sense of - so what I
would like to see is, to push research harder, to develop
pharmaceuticals that have fewer side effects, that do not
result in another dependence.”
Attorney 09In addition, the need to secure access to health insurance
services for prisoners was emphasized, as defense lawyers felt this
provision was under increasing political scrutiny.FIGURE 7 | Room for improvement.May 2020 | Volume 11 | Article 395
Buadze et al. Opioid Agonist Treatment in PrisonDISCUSSION
In the present qualitative study, we investigated how Swiss
defense attorneys view OAT, its accessibility and course in pre-
trial detention as well as during imprisonment in different parts
of Switzerland.
Our results indicate that defense attorneys working closely with
a clientele using opioids view OAT as a “valuable, pragmatic and
economic” medical intervention. In their understanding, the
treatment allows easier contact with their clients, as well as a
more effective defense and goes hand in hand with an improved
legal prognosis. This finding is in line with the research on OAT's
effectiveness, but contrasts with reports from the United States
claiming that “few defense lawyers understand the literature,
science and research that supports their arguments” for OAT in
the proceedings before drug-courts (33). From their statements in
the present study it could be inferred that Swiss defense lawyers had
experienced the difficulties of unaccompanied detoxification in the
sense of “cold-turkey” first-hand. Negative effects of detoxification
are “often associated with a variety of unhealthy behaviors” on re-
entering OAT after prison release and have been documented
elsewhere (34, 35). Jonsen and Stryker warned that detained
persons who ease their withdrawal symptoms without formal
support also put themselves at increased risk by using drugs
available in prison or buying medications from other inmates (36).
Defense attorneys were generally of the opinion that access to
OAT either with methadone or buprenorphine, and in some cases
diacetylmorphine, in the Swiss penal system had improved over
the years. However, they identified a considerable variance in the
accessibility of OAT in different penitentiaries. Unexpectedly this
heterogeneity was not limited to police-custody or pre-trial
detention, but was also described for institutions carrying out
therapeutic measures according to Art. 60 of the Swiss Criminal
Code. The aim of this therapeutic measure is to reduce the risk of
reoffending by an delinquent dependent on psychotropic
substances, whose offence was linked to this dependency, and of
whom it can be said that, with treatment, the risk of further such
acts in connection with this disorder can be reduced. The
treatment is provided in specialized inpatient institutions, or, if
necessary, in a psychiatric clinic. The unavailability and/or forced
discontinuation of OAT in institutions carrying out Art. 60
measures strikes one as especially problematic, considering that
these institutions involve medical professionals in the treatment
process, who should know about the efficacy of this form of
therapy while the unavailability cannot be proven by our
methodical approach, the interviewed individuals perceived the
availability of OAT as not sufficient. This should be subject to
further research.
This significant heterogeneity in access to OAT has also been
reported from 18 other European countries, including Germany
(37). In these countries, too, it can be seen that although OAT is
nominally accessible, its actual implementation varies between
prisons even within the same jurisdiction (38).
Apart from the variance in accessibility, it became apparent
that the continuation of an OAT started outside the prison was
considered to be significantly easier than the initiation of OAT inFrontiers in Psychiatry | www.frontiersin.org 11pretrial detention or during a prison term. This phenomenon has
previously not been reported for Switzerland and, given the
highly successful four pillar drug policy implementation (39,
40), was rather surprising. This restriction concerns in particular
foreign nationals who are not permanent residents of
Switzerland, who are in detention and thus cannot prove that
they have taken part in an OAT, for example in their home
country. The discussion of this problem must remain open and
was not within the scope of the present study. From a scientific
point of view, there is strong evidence that prison-initiated
methadone maintenance leads to an increased likelihood of
entering treatment post-release and is associated with less use
of heroin after release, other opiates and injection drugs (41).
A recurring motive in this context was that, instead of opioid-
agonist medicine, other drugs were prescribed to cope with
symptoms of opioid withdrawal. Benzodiazepines were
mentioned here in particular, but also non-benzodiazepine
sedatives and hypnotics. Although not in line with current
international recommendations for the management of opioid
withdrawal symptoms, which suggest tapered doses of opioid
agonists (42), this course of action has been reported from
correctional institutions elsewhere (34). A major concern
regarding benzodiazepine use in individuals using opioids is
their potential contribution to an increased opioid‐related
mortality as well as the development of a subsequent long term
misuse of this substance (43). Our study revealed that perceived
difficulties with non-opioid agonist medication like
benzodiazepines used to mitigate withdrawal symptoms are
discussed and debated among defense lawyers and clients, but
that these discussions are constrained by the fact that defenders
assess their influence on prison staff as being extremely low.
From the point of view of medical ethics and the rule of law,
the perception of some defense lawyers that access to opioid-
agonist medicine is restricted in order to increase the defendant's
willingness to testify is worrying. Specific examples were given in
particular in connection with the placement of individuals using
opioids in police custody, i.e., in the early stages of criminal
proceedings, since police custody is (according to the Swiss code
of criminal procedure) limited to 24 h. From a medical
perspective, it should not go unmentioned that the
discontinuation of methadone represents a considerable
psychological burden and has been considered a trigger for
suicidal behavior in pre-trial detention (44, 45). Naturally, a
qualitative study cannot give an assessment of the frequency of a
phenomenon. However, future studies, using a different
methodological approach, should review this aspect.
Surprisingly, the defense attorneys were under the impression
that authorities in most correctional institutions still aimed in the
long run at a discontinuation of opioid-agonist medicine and
recommended this over a maintenance approach to the inmates.
Interviewees shared this point of view, despite their overall positive
stance on OAT—a finding that underlines that the stigma associated
with this treatment approach is particularly strong (46, 47) and
further education and training of legal actors may be necessary
In view of the positive results that have been published with
regard to the introduction of OAT from selected Swiss penalMay 2020 | Volume 11 | Article 395
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heterogeneity, not just in terms of access, but also in the course
of OAT and implies that “access” is not synonymous with
“continuation of treatment”. The present study cannot answer
the question of why some Swiss institutions are apparently
enforcing or at least promoting the discontinuation of opioid-
agonist medicine. Various studies have shown that the mortality
rate of detained persons using opioids immediately after release
from closed prison without OAT is increased and remains at an
elevated level (17, 50, 51). The elevated risk of fatal overdoses in this
population has been linked to the loss of tolerance and is estimated
to be three to eight times greater than that during other periods at
liberty (52). Similar findings were recognized early on in
Switzerland (53) and influenced the development of
recommendations by the Swiss Society of Addiction Medicine
(SSAM) and the Federal Office of Public Health (FOPH) that list
the discontinuation of OAT as only one of four treatment options,
explicitly stating: “As OAT is also one of the preventive measures
against overdose deaths, it is preferable that the withdrawal of the
opioid-agonist medicine should take place after discharge” (54, 55).
Stöver et al. have commented on barriers to implementation of
OAT in prison and identified for example a “poor understanding of
opioid dependence as a chronic and recurring disease”, a “mistaken
belief in the benefits of abstinence for drug users”, “socioeconomic
reasons”, a belief that OAT is not compatible with the concept of
prison as a “drug-free zone”, a belief that this form of treatment
undermines efforts to reduce drug supply and amplifies “diversion”
as such (56). It is conceivable that a number of these factors still
play a role in the Swiss prison system, although Switzerland played
a pioneering role in the implementation of OAT.
The majority of participants described a forced tapered
withdrawal from methadone and/or other agonist medicine
that was initiated and driven forward by prison staff or legal
authorities and identified accelerated reduction leading to
suboptimal dosage levels as a major concern for their clients.
Some statements suggest that selected penal institutions show
very little flexibility in dose adjustments, that clients are not
always involved in the decision-making process and that dose
reductions are carried out explicitly against the wish of the
detained person. This indicates that in some Swiss prisons
federal regulations might not be fully implemented, since, for
example, the above-mentioned FOPH recommends that: “Every
person using opioids should have an individualized treatment
that is tailored to their needs and is adapted to the clinical course,
personal motivation and legal circumstances.” It further advises
those involved to “Consider the possibility to revise the decision
as to dose change, within the framework of the requirements of
the respective institution regarding prescription or clinical
evaluation (weekly doctor's visit).”(54).
The importance of OAT for rehabilitation and relapse
prevention was emphasized several times, thus becoming a
recurrent motive amongst defense lawyers. One of the
respondents remarked that OAT is not easily granted in one of
the secure prisons carrying out sentences of indefinite
incarceration because “the idea of rehabilitation does not play
a role there”. This illustrates the extent to which staff attitudesFrontiers in Psychiatry | www.frontiersin.org 12also influence access to medically indicated treatment—a result
that is consistent with international reports on the accessibility of
health services to inmates (57–59).
It should not go unmentioned that, in the opinion of the
defense lawyers, some detained persons are using their stay in
prisons to end OAT on their own initiative. The detained persons
are supported in this by family members. Both aspects were
reported in a similar form from other countries (34).
For some of the interventions reported, it must be noted that
these are not in line with the principle of equivalence, that is,
prisoners shall have access to the health services available in the
country without discrimination on the grounds of their legal
situation and conflict with legal requirements on a federal as well
as, in some cases, on a cantonal level (60). In particular, the
above-mentioned forced discontinuation of OAT against the will
of the detained persons, but more so the termination of OAT for
disciplinary reasons—as described by some defense attorneys—
would be unethical from a medical point of view and contrasts
starkly with recommendations laid out by the Council of Europe
and the perspective of the European Court of Human Rights as
reflected for example in its ruling Wenner vs. Germany.
Surprisingly, the defense lawyers saw little need for action
with regard to OAT. Comparisons were repeatedly made with
the situation in past decades, when accessibility was even more
difficult. The defense lawyers had also subjectively noticed a
decline in the number of clients suffering from heroin addiction,
which is why the strategies applied were assessed positively. In
this context it can be pointed out, that current data shows a stable
prevalence of problematic heroin use with a sharply decreasing
incidence (61, 62). The (subjective) experiences of the attorneys
also coincide with reported declines in drug-related crime and
suggest that the success of Swiss drug policy is palpable on the
practical everyday level of criminal proceedings (63–65).
However a decrease in incidence of problematic heroin use can
and should not justify poor OAT practices.
Comparisons were also made between the accessibility of
opioid-agonist medicine and stimulant medication such as
methylphenidate, which was considered even more difficult to
obtain. Data on the accessibility of methylphenidate in Swiss
prisons does not exist, but a recent study suggests that only a
third of inmates who are diagnosed with ADHD receive
stimulant treatment (Baggio et al., under review).
The aspects that needed—in the eyes of the interviewees—
improvement were not surprising and were largely complementary
in nature. Defense lawyers emphasized the necessity for a more
low-threshold approach to initiation of OAT during pre-trial
detention, were in favor of a smoother transition from pre-trial
to prison, demanded a higher degree of sensitization of authorities
and staff to the needs of detained persons using opioids and
advocated for improvements in their psycho-education and
aftercare after release from prison. Regarding the lobbying for
improved psycho-education, it may be noted that defense lawyers
themselves had begun to advise their clients on drug related health-
issues, e.g. by pointing out the dangers of overdoses after release
from prison, and were thus, without classifying their strategies as
such, educationally active and applying, unbeknownst toMay 2020 | Volume 11 | Article 395
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underlines the importance of imparting knowledge to legal
professionals (31). Defense attorneys' concerns about detainees'
access to medical care are not unfounded. Although the directives
on the provision of medical heath care for persons in detention
stipulate clearly that medical care has to be accessible at a low-
threshold level and should in principle be free of charge, except for
some minor copayments, reality deviates from this rule. Access to
health services for detainees seems to have become more
complicated in recent years and physicians have to deal with
additional work, such as applying for reimbursement of costs
and negotiating with administrative bodies in prison or social
services to provide their patients with adequate health care (67).
Limitations
These results need to be considered within the limitations of the
investigation. First, because this is an exploratory qualitative study
based on a purpose sampling method, the findings on the personal
stance towards OAT cannot be generalized beyond this study
sample. However, with regard to the other themes identified, the
sample represents a group of defense lawyers with multiple years
of experience in providing legal representation to at least 220
defendants using heroin. Second, there are limitations associated
with volunteer bias, to which most studies are also susceptible. The
main reason for non-participation stated was lack of experience
with substance-abusing defendants, followed by lack of time and
lack of interest in the research topic. However, other possible
reasons could include sensitivity regarding the topic.
Since we only interviewed defense lawyers who had
experience with clients using heroin, our findings may not
reflect the attitudes of recently graduated lawyers. As
exploratory research, this study was not driven by a theoretical
framework. Future studies on this subject could, however, use the
insights gained to pursue more focused research.
We also recognize that the results may in part be specific to the
Swiss legal and penal system. Nevertheless, the literature indicates
that similar problems, such as significant heterogeneity in access to
OAT, have also been reported from other European countries.
Our findings provide several relevant insights into views held
by defense lawyers who gathered vast experience during the
height of an opioid crisis and in the following years until today.
Most importantly, our findings are based on defense lawyers'
own reports identifying a range of experiences. These findings
were not limited to predefined experiences, as might occur in a
survey-based research. Furthermore, a written survey of prison
authorities might have increased the likelihood of socially
desirable responses. Such criticism could also have been voiced
if the study had focused on the experiences of current or past
detained persons using opioids themselves.
Conclusions
This research gives additional insight into the accessibility of
OAT and its forced discontinuation in Swiss prisons as
experienced by defense lawyers. Defenders who had been
exposed to the opioid crisis during the course of their legal
career had adopted a positive attitude towards OAT, and
associated it with a stabilizing influence on their clients, anFrontiers in Psychiatry | www.frontiersin.org 13improvement in criminal prognosis and a reduction in
recidivism. They were generally of the opinion that access to
opioid maintenance treatment in the Swiss penal system had
improved over the years, however identified a considerable
variance in the accessibility and the course of OAT in different
penitentiaries, which were mediated by attitudes of staff and
authorities. Based on the assessments of the defense lawyers, it
can be estimated that the initiation of OAT, especially during
times of police-custody and during pre-trial detention is
challenging, especially for clients who have not been enrolled
in OAT prior to being arrested. Furthermore, the predominant
aim of OAT in a variety of Swiss prisons seems, in contrast to the
available medical evidence and the harm-reduction drug policy
implemented, still to focus on a discontinuation of OAT,
mediated by a forced reduction of medication. For some of the
interventions reported, it must be noted that these are not in line
with the principle of equivalence and conflict on a federal as
well as, in some cases, on a cantonal level with legal
requirements, while at the same time starkly contrasting with
recommendations laid out by professional societies, the Council
of Europe and the WHO. The defense lawyers advocated for
improvements in the areas of psycho-education and aftercare
after release from prison of detained persons using opioids and,
in the perceived absence of these, regularly advised their clients
on drug related health-issues, e.g. by pointing out the dangers of
an overdose after release from prison. It may therefore make
sense, alongside other legal professionals such as prosecutors and
judges, to specifically train defenders of a clientele with substance
use dependence on harm reduction measures and make relevant
knowledge easily available to them.DATA AVAILABILITY STATEMENT
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ou torture? Bull Des médecins Suisses (2016) 97(47):1659–62. doi: 10.4414/
bms.2016.05078Frontiers in Psychiatry | www.frontiersin.org 1422. Junod V, Wolff H, Scholten W, Novet B, Greifinger R, Dickson C, et al.
Methadone versus torture: the perspective of the European Court of Human
Rights. Heroin Addict Relat Clin Probl (2018). 20(1):31–6.
23. Kleinig J. The ethics of harm reduction. Subst Use Misuse (2008) 43(1):1–16.
doi: 10.1080/10826080701690680
24. Herdener M, Dürsteler KM, Seifritz E, Nordt C. Changes in substance use in
patients receiving opioid substitution therapy and resulting clinical challenges:
a 17-year treatment case register analysis. Lancet Psychiatry (2017) 4(4):302–
9. doi: 10.1016/S2215-0366(17)30080-9
25. Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in
policy change. Addiction (2010) 105(1):29–37. doi: 10.1111/j.1360-
0443.2009.02741.x
26. McKenzie M, Nunn A, Zaller ND, Bazazi AR, Rich JD. Overcoming obstacles
to implementing methadone maintenance therapy for prisoners: implications
for policy and practice. J Opioid Manage (2009) 5(4):219. doi: 10.5055/
jom.2009.0024
27. Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how
stigma kills. Subst Use Misuse (2018) 53(2):330–3. doi: 10.1080/
10826084.2017.1363238
28. Mitchell SG, Willet J, Monico LB, James A, Rudes DS, Viglioni J, et al.
Community correctional agents' views of medication-assisted treatment:
Examining their influence on treatment referrals and community
supervision practices. Subst Abuse (2016) 37(1):127–33. doi: 10.1080/
08897077.2015.1129389
29. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative
research (COREQ): a 32-item checklist for interviews and focus groups. Int J
Health Care Qual Assur (2007) 19(6):349–57.
30. Liebrenz M, Schneider M, Buadze A, Gehring M-T, Dube A, Caflisch C. High-
dose benzodiazepine users' perceptions and experiences of anterograde
amnesia. J Am Acad Psychiatry Law Online (2016) 44(3):328–37.
31. Canela C, Buadze A, Dube A, Pude I, Nellen R, Jackowski C, et al. How do
legal experts cope with medical reports and forensic evidence? The
experiences, perceptions and narratives of Swiss judges and other legal
experts. Front Psychiatry (2019) 10:18. doi: 10.3389/fpsyt.2019.00018
32. Kaefer F, Roper J, Sinha P. A software-assisted qualitative content analysis of
news articles: Examples and reflections. Forum: Qualitative Social Research
(2015). 16(2).
33. Csete J, Catania H. Methadone treatment providers' views of drug court policy
and practice: a case study of New York State. Harm Reduction J (2013) 10
(1):35. doi: 10.1186/1477-7517-10-35
34. Mitchell SG, Kelly SM, Brown BS, Reisinger HS, Peterson JA, Ruhf A, et al.
Incarceration and opioid withdrawal: the experiences of methadone patients
and out-of-treatment heroin users. J psychoactive Drugs (2009) 41(2):145–52.
doi: 10.1080/02791072.2009.10399907
35. Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, et al. Methadone
continuation versus forced withdrawal on incarceration in a combined US
prison and jail: a randomised, open-label trial. Lancet (2015) 386(9991):350–9.
doi: 10.1016/S0140-6736(14)62338-2
36. Jonsen AR, Stryker JE. (Eds.) The social impact of AIDS in the United States.
Washington, D.C.: National Academy Press (1993).
37. Stöver H, Casselman J, Hennebel L. Substitution treatment in European
prisons: A study of policies and practices in 18 European countries. Int J
Prisoner Health (2006) 2(1):3–12. doi: 10.1080/17449200600743396
38. Michels II, Stöver H, Gerlach R. Substitution treatment for opioid addicts in
Germany. Harm Reduction J (2007) 4(1):5. doi: 10.1186/1477-7517-4-5
39. Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A.
Mortality in heroin-assisted treatment in Switzerland 1994–2000. Drug
Alcohol Depend (2005) 79(2):137–43. doi: 10.1016/j.drugalcdep.2005.01.005
40. Somaini B, Grob P. How and why AIDS changed drug policy in Switzerland. J
Public Health Policy (2012) 33(3):317–24. doi: 10.1057/jphp.2012.20
41. McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A, Friedmann PD,
et al. A randomized trial of methadone initiation prior to release from
incarceration. Subst Abuse (2012) 33(1) :19–29. doi : 10.1080/
08897077.2011.609446
42. World Health Organization, Department of Mental Health, Substance Abuse,
World Health Organization, International Narcotics Control Board and United
Nations Office on Drugs, & Crime. Guidelines for the psychosocially assistedMay 2020 | Volume 11 | Article 395
Buadze et al. Opioid Agonist Treatment in Prisonpharmacological treatment of opioid dependence. World Health Organization
(2009).
43. Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine:
interactions and clinical management. Am J Addict (2010) 19(1):59–72. doi:
10.1111/j.1521-0391.2009.00007.x
44. Humber N, Webb R, Piper M, Appleby L, Shaw J. A national case–control
study of risk factors among prisoners in England and Wales. Soc Psychiatry
Psychiatr Epidemiol (2013) 48(7):1177–85. doi: 10.1007/s00127-012-0632-4
45. Larney S, Gisev N, Farrell M, Dobbins T, Burns L, Gibson A, et al. Opioid
substitution therapy as a strategy to reduce deaths in prison: retrospective
cohort study. BMJ Open (2014) 4(4):e004666. doi: 10.1136/bmjopen-2013-
004666
46. Smith CB. Socio-spatial stigmatization and the contested space of addiction
treatment: remapping strategies of opposition to the disorder of drugs. Soc Sci
Med (2010) 70(6):859–66. doi: 10.1016/j.socscimed.2009.10.033
47. Earnshaw V, Smith L, Copenhaver M. Drug addiction stigma in the context of
methadone maintenance therapy: an investigation into understudied sources
of stigma. Int J Ment Health Addict (2013) 11(1):110–22. doi: 10.1007/s11469-
012-9402-5
48. Lines R, Jürgens R, Betteridge G, Stöver H. Taking action to reduce injecting drug-
related harms in prisons: The evidence of effectiveness of prison needle exchange in
six countries. IJPH (2005) 1: (1):49–64. doi: 10.1080/17449200500157085
49. Favrod-Coune T, Baroudi M, Casillas A, Rieder J-P, Gétaz L, Barro J, et al.
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